Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,910 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,910 Papers indexed
963 Papers AI scored
37,910 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37910 results
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.7/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 70.8; sample size: 30.0; recency: 100.0; abstract quality: 65.0.

B
[Plasma lipidomics-based exploration of potential biomarkers of metastasis in pediatric medulloblastoma].
PMID 41250539 Published: 2025-11-15 Ingested: 2026-08-02 12:05 AM Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
AI -
Base 72.65
Rank 72.65
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.7/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 40.8; sample size: 30.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Base 72.64
Rank 72.64
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 38.2; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
Clinical Outcomes of Stereotactic Body Radiotherapy in Hepatocellular Carcinoma Patients With Child-Turcotte-Pugh B Liver Dysfunction.
PMID 42519550 Published: 2026-06-25 Ingested: 2026-08-02 12:07 AM Journal of clinical and experimental hepatology
AI -
Base 72.64
Rank 72.64
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 75.7; sample size: 40.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Base 72.64
Rank 72.64
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 58.2; sample size: 90.0; recency: 100.0; abstract quality: 85.0.

B
Use of High-Flow Nasal Cannula Therapy in Pediatric Hematology/Oncology Patients Admitted to the Pediatric Intensive Care Unit with Acute Respiratory Failure.
PMID 40263901 Published: 2025-04-23 Ingested: 2026-08-02 12:03 AM Hematology/oncology and stem cell therapy
AI -
Base 72.64
Rank 72.64
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 38.2; sample size: 70.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 75.7; sample size: 50.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 72.64
Rank 72.64
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 38.2; sample size: 70.0; recency: 90.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 58.2; sample size: 30.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 72.64
Rank 72.64
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 58.2; sample size: 40.0; recency: 80.0; abstract quality: 100.0.

B
AI -
Base 72.64
Rank 72.64
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 93.2; sample size: 40.0; recency: 80.0; abstract quality: 85.0.

B
Pediatric AML CAR T cell therapy.
PMID 42519395 Published: 2026-06-30 Ingested: 2026-08-02 12:07 AM Molecular therapy. Oncology
AI -
Base 72.62
Rank 72.62
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 72.6/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 93.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

Previous
Page 456 of 3160
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic